Key Takeaway: The article features a Q&A with Lisa Ricciardi, CEO of Cognition Therapies, Inc., discussing patient selection. It emphasizes the importance of finding the right patients for their therapies. However, the text primarily serves as a disclaimer regarding third-party websites and does not provide specific insights into the company's operations or strategies.
Price reaction · baseline $1.97 (2024-03-11 close) · hit after-hours · clean, no other CGTX news in the window
day 0 close
-6.6%
day 1 · peak
-8.6%
day 3
-7.6%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.